BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21601641)

  • 21. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.
    Sauter CS; Matasar MJ; Meikle J; Schoder H; Ulaner GA; Migliacci JC; Hilden P; Devlin SM; Zelenetz AD; Moskowitz CH
    Blood; 2015 Apr; 125(16):2579-81. PubMed ID: 25758829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
    Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
    Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
    Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
    Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China.
    Xie Y; Wang X; Leng X; Zheng W; Ping L; Zhang C; Liu W; Deng L; Wu M; Song Y; Zhu J
    Ann Hematol; 2020 Mar; 99(3):549-555. PubMed ID: 31980860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma.
    Mocikova H; Pytlik R; Markova J; Steinerova K; Kral Z; Belada D; Trnkova M; Trneny M; Koza V; Mayer J; Zak P; Kozak T
    Leuk Lymphoma; 2011 Sep; 52(9):1668-74. PubMed ID: 21699377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
    Noring K; Carlsten M; Sonnevi K; Wahlin BE
    BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
    Cherng HJ; Xu G; Feng L; Steiner R; Fayad L; Strati P; Nair R; Nastoupil LJ; Lee HJ; Neelapu SS; Flowers CR; Rodriguez M; Wang M; Hagemeister F; Pinnix CC; Ramdial J; Srour S; Nieto Y; Rezvani K; Champlin R; Kebriaei P; Westin J; Macapinlac HA; Shpall E; Ahmed S
    Br J Haematol; 2023 Jan; 200(1):35-44. PubMed ID: 36068929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
    Moskowitz CH; Yahalom J; Zelenetz AD; Zhang Z; Filippa D; Teruya-Feldstein J; Kewalramani T; Moskowitz AJ; Rice RD; Maragulia J; Vanak J; Trippett T; Hamlin P; Horowitz S; Noy A; O'Connor OA; Portlock C; Straus D; Nimer SD
    Br J Haematol; 2010 Mar; 148(6):890-7. PubMed ID: 20085577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
    Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
    Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
    Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation.
    Filmont JE; Gisselbrecht C; Cuenca X; Deville L; Ertault M; Brice P; De Kerviler E; Briere J; Larghero J; Moretti JL; Mounier N
    Cancer; 2007 Sep; 110(6):1361-9. PubMed ID: 17623832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
    Stamatoullas A; Brice P; Gueye MS; Mareschal S; Chevallier P; Bouabdallah R; Nguyenquoc S; Francois S; Turlure P; Ceballos P; Monjanel H; Bourhis JH; Guillerm G; Mohty M; Biron P; Cornillon J; Belhadj K; Bonmati C; Dilhuydy MS; Huynh A; Bernard M; Chrétien ML; Peffault de Latour R; Tilly H
    Bone Marrow Transplant; 2016 Jul; 51(7):928-32. PubMed ID: 27042842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
    Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.
    Kasamon YL; Wahl RL; Ziessman HA; Blackford AL; Goodman SN; Fidyk CA; Rogers KM; Bolaños-Meade J; Borowitz MJ; Ambinder RF; Jones RJ; Swinnen LJ
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):242-8. PubMed ID: 19167684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
    Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
    Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
    Jabbour E; Hosing C; Ayers G; Nunez R; Anderlini P; Pro B; Khouri I; Younes A; Hagemeister F; Kwak L; Fayad L
    Cancer; 2007 Jun; 109(12):2481-9. PubMed ID: 17497648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.